Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase®" or the " Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements (" Financial Statements").
Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025.
Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com.
An archived version will be available on the website following the conference call.
1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2786/253913_18d14c9a14378a83_001full.jpg
Financial Highlights
For the three-month period ended March 31, 2025:
Total revenue was $91,190, compared to $175,554 in Q1 2024, a 48% year-over-year decrease.
Cost of sales was $77,896 (85% of revenue), resulting in a gross margin of $13,294 (15% of revenue), down from $62,114 (35% of revenue) in Q1 2024.
Selling expenses were $68,143, essentially flat compared to $67,552 in the prior year.
Administrative expenses rose to $555,074 from $511,495, a 9% increase driven primarily by professional fees and stock-based compensation.
Research and development expenses were $877,670, up from $756,380, reflecting increased activity to support Study II progress.
Net loss for the period was $1,471,250, compared to $1,266,711 in Q1 2024. This includes $220,538 in non-cash charges such as amortization and stock-based compensation.
Operational Highlights
Private Placements
On March 10, 2025, the Company closed a non-brokered private placement of 1,034,002 units at $0.30 per unit for gross proceeds of $310,201. Each unit consisted of one common share and one non-transferable common share purchase warrant exercisable at $0.45 for five years. Net proceeds were $304,633, after transaction costs.
On April 22, 2025, the Company completed another non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years.
The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws.
Herpes Simplex Virus ("HSV") Treatment Program
Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice (" GLP") toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved.
Phase II Bladder Cancer Study Update ("Study II")
82 patients have been treated with the Study Procedure, representing approximately 91% of the total targeted enrollment of 90 evaluable patients.
69 patients have completed their 90-day assessment and are considered evaluable for interim efficacy analysis.
13 additional patients are pending their 90-day assessment and will be included in future efficacy updates once evaluations are complete.
Interim Clinical Results
For the primary endpoint of Study II (Complete Response (" CR") at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response (" IR") (negative cystoscopy and positive or suspicious urine cytology), the Total Response ("TR") increases to 70%.
This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer.
For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure).
For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events (" SAEs") directly related to the Study Drug or Study Device.
Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years.
Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase.
Theralase® is on track to complete enrollment in Study II by the summer of 2025.
This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026.
Upon follow-up of all patients, the Company plans to submit a New Drug Application ("NDA") to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027.
As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®.
To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning:
Licensing of the light-activated Ruvidar® for BCG-Unresponsive NMIBC CIS
Collaborative research focused on investigating light-activated Ruvidar® in the treatment of NMIBC
Collaborative research focused on combining Ruvidar® with other FDA approved drugs
In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases.
Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time.
Additional Oncology Targets
Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®.
Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers.
Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the "tumour's damage zone" and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body.
Rutherrin®, if clinically proven, will be able to "hunt" and "localize" into cancer cells and when activated by radiation "destroy" them; wherever, they may reside in the body.
The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications:
1) Glio Blastoma Multiforme (" GBM") Brain Cancer Treatment
2) Non-Small Cell Lung Cancer (" NSCLC") Treatment
3) Pancreatic Cancer
4) Colorectal Cancer
5) Muscle Invasive Bladder Cancer (" MIBC") Treatment
6) Herpes Simplex Virus (" HSV-1") Topical Treatment for Cold Sore Lesions
For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at www.sedarplus.ca.
About Ruvidar®:
Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements (" FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words " may, " should", " will", " anticipates", " believes", " plans", " expects", " estimate", " potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Northern Ontario ticket scores $34M in Lotto 6/49 draw
A pair of Lotto 6/49 tickets are seen in this undated image. (THE CANADIAN PRESS/Richard Plume) For the second time in recent weeks, Ontario has claimed the Lotto 6/49 Gold Ball jackpot – this time with a winning ticket worth $34 million sold in North Bay. The Ontario Lottery and Gaming Corporation (OLG) confirmed the winning ticket from the June 21 draw was purchased in the northern Ontario city. 'We are anxiously waiting for the ticket holder(s) to come forward so we can celebrate this incredible win with them very soon,' said OLG spokesperson Tony Bitonti in an email to CTV News. Tony Bitonti An undated photo of OLG spokesperson Tony Bitonti. (Tony Bitonti/LinkedIn) This marks the second consecutive Gold Ball jackpot win in the province. On May 7, a $60 million prize was won through a ticket bought on though that winner has yet to claim their prize. While one lucky player took home the $34 million jackpot, OLG noted in a news release that an additional 289,090 Lotto 6/49 prizes were won across Ontario in the same draw. Lotto 6/49 offers two multi-million-dollar jackpots each week – the Classic Draw with a fixed $5 million prize and the Gold Ball Draw, which guarantees at least $1 million or a growing jackpot that starts at $10 million. More details on the game can be found on OLG's official website. What are your odds of winning the $55M jackpot? A Lotto 6/49 ticket is show being printed from a lottery kiosk in April 2013. (File photo/CTV News) Play responsibly 'OLG supports safe play and wants to keep the fun in the game,' said OLG. 'That's why OLG is proud to be a leader in promoting responsible gambling with our globally recognized Playsmart program.' Playsmart offers information on gambling games. If you or someone you know is struggling with a problem help is available.
CBC
3 hours ago
- CBC
Canadian ambassador says there's a 'good path forward' to a trade deal with the U.S.
Social Sharing Canada's ambassador to the United States, Kirsten Hillman said she "firmly" believes that both countries could reach a trade deal within the 30-day deadline discussed at the G7 summit in Alberta last week. "We can't do anything to force the U.S. side to come to a deal, but we do think we have a good path forward if we're able to take it," she said during an interview on Rosemary Barton Live that aired on Sunday. Hillman said it's "too soon to tell" whether all U.S. tariffs imposed on Canada will be removed, and she stopped short of saying whether the federal government is willing to accept the continuation of some tariffs. "These are things that will work themselves out in the next number of weeks," she said. Canada is fighting for "open trade and stability" for Canadian workers and businesses, Hillman said during the interview. WATCH | Canadian ambassador to U.S. discusses ongoing trade talks: Canadian ambassador to U.S. 'firmly' believes in path to trade deal 4 hours ago Duration 9:16 Chief political correspondent Rosemary Barton speaks with Canadian Ambassador to the United States Kirsten Hillman about the ongoing negotiations between Ottawa and Washington. Hillman gets expanded role in Washington Prime Minister Mark Carney appointed Hillman as Canada's chief negotiator with the U.S. amid heightened trade tensions, CBC News has learned. This role comes in addition to her duties as Canada's ambassador to the U.S. Hillman previously worked on the team negotiating the Canada-United States-Mexico Agreement during U.S. President Donald Trump's first term and as Canada's chief negotiator for the Comprehensive and Progressive Agreement for Trans-Pacific Partnership. Her expanded duties now position her in bilateral talks as U.S. Trade Representative Jamieson Greer's counterpart. Trade and defence talks continuing Since Carney and Trump set the 30-day deadline while meeting at the G7 in Kananaskis, Alta., on June 16, Hillman has had three meetings with her U.S. counterparts — one immediately following the leaders' bilateral, the second on the following day with Greer and another on Friday that included Intergovernmental Affairs Minister Dominic LeBlanc, who is also the minister responsible for Canada-U.S. trade. More talks are planned throughout this week. The conversations with the U.S. are focused on different topics, including fentanyl, border security and Arctic defence, although the leaders are focused on tariffs. Hillman said it's still unclear whether defence and trade will be part of one deal coming within the next 30 days. Trump has said "many times" that he likes tariffs, Hillman said. "It's up to Canada to demonstrate we can achieve the same goals with the United States through other means that don't necessarily involve these punishing tariffs, especially on strategic goods." WATCH | PM may raise counter-tariffs on U.S. steel, aluminum if deal delayed: Canada to limit steel imports, may hike U.S. counter-tariffs next month 3 days ago Duration 2:20 Prime Minister Mark Carney has announced limits to foreign steel imports in a bid to prop up Canada's steel industry, which has been hit hard by the U.S. trade war. Canada may hike counter-tariffs on U.S. steel and aluminum if a deal isn't reached by July 21. Steel tariffs still at 50% Just days after Canada and the U.S. set a 30-day deadline, Carney signalled he's willing to go higher with Canada's retaliatory tariffs if no agreement is reached. Canada's counter-tariffs on steel will go up or down, depending on trade progress by July 21, in response to U.S. metal tariffs that are now at 50 per cent. Industry Minister Mélanie Joly told CBC Power & Politics host David Cochrane that Canada is taking "measures like [it's] never done" in the free-trade era to protect the steel and aluminum sectors.
CTV News
3 hours ago
- CTV News
15K Rotarians from 140 countries celebrate community at Calgary convention
Mark Starratt is the co-chair of the host organizing committee of 2025 Rotary International Conventional, which has 15,000 people from 140 different countries attending. Last week, Alberta hosted the G7, which featured global leaders from around the world gathering together in Kananaskis Country to try to solve a few of the world's problems. This week, Calgary is hosting the 2025 Rotary International Convention, which features 15,000 ordinary folks from 140 countries around the world gathering together at BMO Centre in Stampede Park to try to solve a few of the world's problems. "I don't think we have enough time to talk about the variety of things that are being talked about, but it's everything from peace and conflict resolution to polio eradication to literacy, maternal health, and community engagement,' said Mark Starratt, the co-chair of the host organizing committee. 'There's just so many things going on at this convention. It's hard to put a pulse on just one thing." Starratt said there are 13 Rotary Clubs in Calgary and more than 45 in southern Alberta and Saskatchewan, who represent a sliver of the organization's 1.2 million people from 46,000 different clubs. When you put that kind of people to work trying to solve a problem, you can get a lot done, said Rotary International General Secretary and CEO John Hewko. 'Rotary, really, back in 1985, had the the audacity to say we are going to eradicate a disease from the face of the earth,' Hewko said. 'Smallpox have just been eradicated, and we -- to celebrate our 75th anniversary -- said we're going to tackle eradicating polio. John Hewko, Rotary International CEO John Hewko, Rotary International president and CEO (Tyler Barrow, CTV Calgary) 'We were joined by the WHO, UNICEF, CDC, and, more recently, the Gates Foundation and GAVI to create the Global Polio Eradication Initiative. 'We started with 125 countries that had polio back then,' Hewko said. 'We're now down to just two: Afghanistan and Pakistan, where the virus is still circling. So we're on the verge of eradicating polio and leaving a legacy for as long as mankind inhabits the earth.' Hewko said Rotarians around the world have contributed US $2.9 billion to the effort over 40 years, and recently Gates announced he would chip in two dollars for every dollar raised by Rotarians. Not bad for a gathering of not-so-ordinary folks. 'What the polio eradication effort demonstrates is the power of the individual, the power of grassroots organizations to unite together around the cross to drive change and to really make a difference in the world,' Hewko said. Locally, two Calgary Rotary Clubs joined with the Flames Foundation Friday to announce a $3 million donation to build four sports zones in different communities across the city. The convention is believed to be one of the largest Calgary has ever hosted and if there's a problem to be solved in Calgary this week, it might be finding a vacant hotel room or a dinner reservation at a restaurant. All those visitors are expected to book 30,000 hotel room nights and drop around $81 million into the local economy. 'We're delighted to be here in in Calgary,' Hewko said. 'And of course, we're going to be taking advantage of the incredible hospitality of the of the people of Calgary and the City of Calgary.' Rotary International Convention 2025 continues through May 25.
